Synergistic activities of clofazimine with moxifloxacin or CAPREOMYCIN (cas 11003-38-6) against Mycobacterium tuberculosis in China

Add time:08/15/2019    Source:sciencedirect.com

Clofazimine (CFZ) is a promising candidate drug for use in the management of multidrug-resistant tuberculosis (MDR-TB) patients. In this study, the minimum inhibitory concentration (MIC) method and checkerboard method were used to investigate potential synergies between CFZ and moxifloxacin (MOX) or CAPREOMYCIN (cas 11003-38-6) (CAP). 30 Mycobacterium tuberculosis strains were collected, including 13 MDR strains, 2 extensive drug- resistant (XDR) strains, 3 pan-sensitive strains and 12 strains resistant to other drugs. When the minimum fractional inhibitory concentration indexes (FICIs) were calculated, synergy was found in 21 (70.00%) M. tuberculosis strains against the CFZ/CAP combination and 29 (96.67%) against the CFZ/MOX combination. When the maximum FICIs were calculated, 10 out of 15 MDR/XDR strains and 2 out of 15 other drug-resistant or pan-sensitive strains showed antagonism against the CFZ/CAP combination, whilst 8 out of 15 MDR/XDR strains and 1 out of 15 other drug-resistant or pan-sensitive strains showed antagonism against the CFZ/MOX combination, respectively. In conclusion, these findings demonstrate that the combination of CFZ and MOX shows better synergism than the combination of CFZ and CAP. The MDR/XDR isolates are more likely to show antagonism than the other drug-resistant or pan-sensitive strains in both CFZ/MOX and CFZ/CAP combinations. Taken together, we suggest that CFZ, in combination with MOX, may be a promising drug regimen for the treatment of MDR-TB, especially for the susceptible M. tuberculosis infectious.

We also recommend Trading Suppliers and Manufacturers of CAPREOMYCIN (cas 11003-38-6). Pls Click Website Link as below: cas 11003-38-6 suppliers

Prev:Isolation and identification of four major impurities in CAPREOMYCIN (cas 11003-38-6) sulfate
Next:Pharmaceutics, Drug Delivery and Pharmaceutical TechnologyA Spray-dried Combination of CAPREOMYCIN (cas 11003-38-6) and CPZEN-45 for Inhaled Tuberculosis Therapy)